COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
29/07/2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4: [...]
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
29/07/2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
29/07/2025
- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic [...]
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
29/07/2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
Larimar Therapeutics Announces Proposed Underwritten Public Offering
29/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
29/07/2025
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with [...]
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
29/07/2025
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, [...]
Inventiva publie ses informations financières préliminaires du premier semestre 2025¹
29/07/2025
Trésorerie et équivalents de trésorerie de 122,1 millions d’euros et 24,6 millions d’euros de dépôts à court terme 2 au 30 juin 2025 Chiffre d’affaires de 4,5 millions d’euros au premier semestre 2025 Daix (France), New [...]
2025 Half-Year results
29/07/2025
Press release Group’s financial position strengthened six months ahead of schedule Guidance confirmed Successful completion of the plan to strengthen the Group’s financial position €1.5-billion plan to strengthen the [...]
Résultats semestriels 2025
29/07/2025
Communiqué de presse Résultats au 30 juin 2025 S tructure financière renforcée avec 6 mois d’avance Objectifs confirmés Succès du plan de renforcement de la structure financière : Plan de renforcement de la structure [...]
Belly Fat Burner: Why Men and Women are Using Strong Over the Counter Diet Supplements like PhenQ to Lose Stubborn Abdominal Fat
29/07/2025
New York City, NY, July 29, 2025 (GLOBE NEWSWIRE) -- In 2025, PhenQ is setting a new standard for belly fat burners with its research-driven, natural solution, providing powerful, long-lasting support for a slimmer, [...]
LifeLabs Deepens Support to Communities Impacted by Saskatchewan Wildfires with an Additional $5,000 Donation
29/07/2025
Toronto, ON, July 29, 2025 (GLOBE NEWSWIRE) -- As wildfires continue to impact communities across Saskatchewan, LifeLabs is pleased to deepen its commitment to relief efforts, contributing an additional $5,000. This [...]
Hapbee Launches Integrated Affiliate and Ambassador Program to Accelerate Growth and Community Expansion
29/07/2025
With trusted names like Gary Brecka, Ben Greenfield, Dave Asprey, and NBA champions Jaylen Brown and Jason Kidd using Hapbee, the company launches its next phase of growth by activating its global community through a [...]
First-half 2025 results
29/07/2025
Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in the upper part of the range, supported by thorough execution of the FOCUS-27 plan, and despite more [...]
Résultats du premier semestre 2025
29/07/2025
Communiqué de presse Paris, le 29 juillet 2025 Objectif de marge de Core EBITDA comprise entre 7% et 9% confirmé ; avec l’ambition d’atteindre le haut de cette fourchette, portée par la mise en œuvre rigoureuse du plan [...]
EssilorLuxottica: Publication of the 2025 Interim Financial Report
29/07/2025
Publication of the 2025 Interim Financial Report Paris, France (29 July 2025 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 28, 2025 to approve the condensed consolidated interim financial [...]
EssilorLuxottica: Mise à disposition du Rapport financier semestriel 2025
29/07/2025
Mise à disposition du Rapport financier semestriel 2025 Paris, France (29 juillet 2025 – 18h30) – Le Conseil d’administration d’EssilorLuxottica, qui s’est réuni le 28 juillet 2025, a arrêté les comptes consolidés [...]
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
29/07/2025
Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis ( 3) and at constant exchange rates (CER) EBITDA ( 1) of € 496.3 million, +9.6%, margin on revenue of 37. [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2025
29/07/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 21 juillet au 25 juillet 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]

Pages